Abstract
Purpose :
This descriptive epidemiological study aims to provide a comprehensive analysis of the geographic distribution of AMD clinical trials in the United States and discuss the factors influencing their location. This investigation attempts to improve understanding of the distribution of AMD trials within the United States, as well as the respective contributions of various sectors (private, academic, industry) to AMD clinical trial sites. Furthermore, the objective of this study is to emphasise discrepancies and call for increased funding and trial sites in regions that are underrepresented (in contrast to the distribution of AMD patients in the US) where necessary.
Methods :
This was a cross-sectional, retrospective, and descriptive epidemiological study that examined 3030 total clinical trials related to AMD over 20 years from January 1, 2002, to December 31, 2021. Clinical trials were screened for AMD, US trial location, study completion, and the enrolment of more than 50 patients on Clinicaltrials.gov. Clinical trials are stratified into the four US Census-Bureau regions and by sector (private, academic, industry).
Results :
Majority of trials (96.20%) had unknown exact trial locations from the total sample. Among the known sectors, the highest participation is observed in the private sector (44.69%), followed by academic (9.74%), industry (13.63%), and the least in the unknown sector (28.15%). Regionally, the South exhibits the highest participation rate (1.19%), while the Midwest, Northeast, and West regions have relatively lower participation rates.
Conclusions :
In conclusion, this study underscores the significance of clinical trials in advancing AMD understanding and treatment. The large number of trials with unknown locations calls for improved transparency. It's crucial to address these discoveries to ensure fair access to trials and promote comprehensive advancements in AMD research.
This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.